Home » HemoSonics’ Quantra QPlus System Earns De Novo Authorization
HemoSonics’ Quantra QPlus System Earns De Novo Authorization
The FDA granted HemoSonics de novo marketing authorization for its Quantra Hemostasis Analyzer platform, a device that checks a patient’s blood coagulation status.
The point-of-care ultrasound system gives rapidviscoelastic results in 15 minutes or less, with hands-on time of less than a minute.
The device uses a sealed consumable cartridge to conduct a panel of viscoelastic blood coagulation tests. The results can be used in managing critical bleeding after cardiac and orthopedic surgeries.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct